What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Satoshi Morita spends much of his time researching Internal medicine, Surgery, Oncology, Lung cancer and Gastroenterology.
His Internal medicine study which covers Cardiology that intersects with Proportional hazards model.
Satoshi Morita interconnects Stomach cancer, Cancer and Early Gastric Cancer in the investigation of issues within Surgery.
The Oncology study combines topics in areas such as Clinical trial, Phases of clinical research, Carboplatin, Meta-analysis and Docetaxel.
The study incorporates disciplines such as Carcinoma, Progression-free survival and Epidermal growth factor receptor in addition to Lung cancer.
His Gastroenterology research integrates issues from Intention-to-treat analysis, Tegafur, Regimen, Standard treatment and Colorectal cancer.
His most cited work include:
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR (3849 citations)
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2971 citations)
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer (579 citations)
What are the main themes of his work throughout his whole career to date?
Satoshi Morita mainly focuses on Internal medicine, Oncology, Surgery, Gastroenterology and Cancer.
Chemotherapy, Phases of clinical research, Lung cancer, Breast cancer and Clinical endpoint are among the areas of Internal medicine where the researcher is concentrating his efforts.
Specifically, his work in Lung cancer is concerned with the study of Gefitinib.
His work focuses on many connections between Oncology and other disciplines, such as Regimen, that overlap with his field of interest in Docetaxel.
His research on Surgery often connects related areas such as Gastrectomy.
His research integrates issues of Adverse effect, Neutropenia and Hazard ratio in his study of Gastroenterology.
He most often published in these fields:
- Internal medicine (64.30%)
- Oncology (37.74%)
- Surgery (19.25%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.30%)
- Oncology (37.74%)
- Gastroenterology (14.52%)
In recent papers he was focusing on the following fields of study:
Satoshi Morita focuses on Internal medicine, Oncology, Gastroenterology, Hazard ratio and Breast cancer.
His Internal medicine research focuses on Phases of clinical research, Chemotherapy, Bevacizumab, Clinical endpoint and Cancer.
Satoshi Morita works in the field of Oncology, namely Lung cancer.
Lung cancer is often connected to Epidermal growth factor receptor in his work.
His Gastroenterology research focuses on Adverse effect and how it connects with Pharmacokinetics and Toxicity.
In his research, Surrogate endpoint is intimately related to Randomized controlled trial, which falls under the overarching field of Hazard ratio.
Between 2018 and 2021, his most popular works were:
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial (147 citations)
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. (69 citations)
- Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. (32 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His scientific interests lie mostly in Internal medicine, Oncology, Gastroenterology, Hazard ratio and Lung cancer.
His Oncology research is multidisciplinary, incorporating elements of Bevacizumab, Progressive disease, Cyclophosphamide and Docetaxel.
His Bevacizumab research incorporates elements of T790M and Erlotinib.
His Gastroenterology research incorporates themes from Organ transplantation, Rheumatology, Adverse effect and Hepatitis B virus.
His Hazard ratio research includes elements of Randomized controlled trial, Darbepoetin alfa, Kidney transplantation, Dialysis and Abdominal surgery.
His Lung cancer research is multidisciplinary, relying on both Grading, Progression-free survival and Epidermal growth factor receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
